Clinical trial NCT01016665 - References

Breast Cancer — Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy

Citation(s)

•   Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ
  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol. 2005 Nov;16(11):1723-39. Epub 2005 Jun 24. Review.
•   Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P
  Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003 Jan 25;361(9354):296-300. Review.
•   Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR
  The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 2000 Jun;6(
•   Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE
  Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2
•   Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R
  Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Canc
•   Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G; IMPACT Trialists
  Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or
•   Dowsett M
  Biomarker investigations from the ATAC trial: the role of TA01. Breast Cancer Res Treat. 2004;87 Suppl 1:S11-8.
•   Dowsett M
  Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003 Jan;9(1 Pt 2):502S-10S. Review.
•   Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.
•   Ellis MJ, Ma C
  Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105 Suppl 1:33-43. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):371.
•   Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M
  Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteri
•   Harvey JM, Clark GM, Osborne CK, Allred DC
  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May;17(5):1474-81.
•   Konstantinidou AE, Korkolopoulou P, Patsouris E
  Apoptotic markers for tumor recurrence: a minireview. Apoptosis. 2002 Oct;7(5):461-70. Review.
•   Macaskill EJ, Renshaw L, Dixon JM
  Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer. Oncologist. 2006 Nov-Dec;11(10):1081-8. Review.
•   Miller WR, Dixon JM, Cameron DA, Anderson TJ
  Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):103-7.
•   Musgrove EA, Sutherland RL
  Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009 Sep;9(9):631-43. doi: 10.1038/nrc2713. Review.

Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study

Details for clinical trial NCT01016665